Biogen Inc. BIIB
Set alert
At close · Nov 2
After hours · Nov 2, 4:00 PM ET
- YTD
- +41.49%
- 1 year
- +61.41%
- Open
- 253.81
- Prev close
- 253.62
- Mkt cap
- 36.81B
- Vol
- 1.17M
- Avg vol
- 1.04M
- EPS
- 2.27
- P/E
- 109.70
- Div yield
- 0.00%
More statistics
- Low
- 247.91
- High
- 255.53
- Forward P/E
- 15.29
- Beta
- 0.09
- Short ratio
- 4.46
- Inst. own
- 99.78%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 5, 2027
- 50-d avg
- 227.08
- 200-d avg
- 201.18
- 1y target
- 264.23
5D chart
Events in this range
- Oct 28, 2026Earnings: 2.62; estimate 1.99; surprise 31.66%
- Oct 29, 2026Rating: Morgan Stanley · Equal-Weight → Equal-Weight
- Oct 29, 2026Rating: RBC Capital · Outperform → Outperform
- Oct 29, 2026Rating: Argus Research · Hold → Buy
- Oct 29, 2026Rating: Canaccord Genuity · Buy → Buy
- Nov 2, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Nov 2, 2026Rating: Guggenheim · Buy → Buy
Signals (156)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Nov 2, 3:35 PM | 11 hours ago |
| SMA: Bullish | Nov 2, 3:35 PM | 11 hours ago |
| SMA: Bearish | Nov 2, 3:30 PM | 11 hours ago |
| SMA: Bearish | Nov 2, 3:30 PM | 11 hours ago |
| SMA: Bullish | Nov 2, 3:05 PM | 11 hours ago |
| SMA: Bullish | Nov 2, 2:55 PM | 11 hours ago |
| SMA: Bearish | Nov 2, 2:35 PM | 12 hours ago |
| SMA: Bullish | Nov 2, 2:30 PM | 12 hours ago |
| MACD: Buy Signal | Nov 2, 2:30 PM | 12 hours ago |
| SMA: Bearish | Nov 2, 2:05 PM | 12 hours ago |
| SMA: Bullish | Nov 2, 2:00 PM | 12 hours ago |
| MACD: Sell Signal | Nov 2, 1:30 PM | 13 hours ago |
| SMA: Bearish | Nov 2, 12:40 PM | 14 hours ago |
| SMA: Bullish | Nov 2, 12:35 PM | 14 hours ago |
| SMA: Bearish | Nov 2, 12:30 PM | 14 hours ago |
| SMA: Bullish | Nov 2, 12:05 PM | 14 hours ago |
| MACD: Buy Signal | Nov 2, 12:05 PM | 14 hours ago |
| MACD: Sell Signal | Nov 2, 12:00 PM | 14 hours ago |
| SMA: Bearish | Nov 2, 11:55 AM | 14 hours ago |
| SMA: Bullish | Nov 2, 11:45 AM | 15 hours ago |
Newest 20 of 156.
News
-
17 hours ago benzinga.com
Guggenheim Maintains Buy on Biogen, Raises Price Target to $300
Guggenheim analyst Yatin Suneja maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $280 to $300.
18 hours ago benzinga.com
Regeneron Pharmaceuticals To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Monday
Analysts upgraded MHK and CRWD, downgraded PFSI, cut ABOS’s target, and raised targets for NRXP, REGN and NTSK.
-
19 hours ago benzinga.com
HC Wainwright & Co. Maintains Buy on Biogen, Raises Price Target to $270
HC Wainwright & Co. analyst Ananda Ghosh maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $251 to $270.
3 days ago benzinga.com
Incyte To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Friday
Analysts raised targets for Cheniere and Incyte, while cutting Stryker, Roblox, Intel and Honeywell; Bright Horizons was downgraded.
-
4 days ago benzinga.com
Canaccord Genuity Maintains Buy on Biogen, Raises Price Target to $272
Canaccord Genuity analyst Sumant Kulkarni maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $248 to $272.
-
4 days ago benzinga.com
Argus Research Upgrades Biogen to Buy, Announces $280 Price Target
Argus Research analyst Jasper Hellweg upgrades Biogen (NASDAQ:BIIB) from Hold to Buy and announces $280 price target.
-
4 days ago benzinga.com
RBC Capital Maintains Outperform on Biogen, Raises Price Target to $272
RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $256 to $272.
-
4 days ago benzinga.com
Morgan Stanley Maintains Equal-Weight on Biogen, Raises Price Target to $238
Morgan Stanley analyst Matthew Harrison maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and raises the price target from $231 to $238.
-
4 days ago benzinga.com
TD Cowen Maintains Buy on Biogen, Raises Price Target to $260
TD Cowen analyst Phil Nadeau maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $250 to $260.
-
4 days ago benzinga.com
Wedbush Maintains Neutral on Biogen, Raises Price Target to $225
Wedbush analyst Laura Chico maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $212 to $225.
-
4 days ago benzinga.com
Truist Securities Reiterates Buy on Biogen, Raises Price Target to $260
Truist Securities analyst Danielle Brill reiterates Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $235 to $260.
4 days ago benzinga.com
Microsoft To Rally More Than 22%? Here Are 10 Top Analyst Forecasts For Thursday
Analysts raised targets for Microsoft, VF, Glaukos, Hilton, AxoGen and Brinker; Renasant’s target was cut and its rating downgraded.
4 days ago benzinga.com
These Analysts Increase Their Forecasts On Biogen After Upbeat Q3 Results
Biogen Inc (NASDAQ:BIIB) on Wednesday posted better-than-expected earnings for the third quarter.
4 days ago benzinga.com
These Analysts Increase Their Forecasts On Biogen After Upbeat Q3 Results
Biogen beats Q3 estimates, narrows FY2026 EPS outlook, and sees analysts raise price targets to $290; shares dip 0.3% premarket.
-
4 days ago benzinga.com
Baird Maintains Outperform on Biogen, Raises Price Target to $290
Baird analyst Brian Skorney maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $250 to $290.
-
4 days ago benzinga.com
Needham Maintains Buy on Biogen, Raises Price Target to $290
Needham analyst Ami Fadia maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $256 to $290.
4 days ago globenewswire.com
Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026
Diranersen late-breaking symposium will feature 96-week long-term extension data and additional 76-week biomarker and clinical data from the Phase 2 CELIA study in early Alzheimer's disease Lecanemab…
5 days ago marketbeat.com
Biogen Q3 Earnings Call Highlights
Biogen NASDAQ: BIIB reported third-quarter 2026 revenue growth of 11% year over year, supported by its acquisition of Apellis and continued expansion of its growth-product portfolio. Management said…
5 days ago seekingalpha.com
Biogen Inc. (BIIB) Q3 2026 Earnings Call Transcript
Biogen Inc. ( BIIB ) Q3 2026 Earnings Call October 28, 2026 8:30 AM EDT Company Participants Tim Power - Head of Investor Relations Christopher Viehbacher - President, CEO & Director Priya Singhal -…
5 days ago zacks.com
BIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View Tightened
Biogen's Q3 earnings and revenues beat estimates as growth drugs drive sales, while the company tightens its 2026 adjusted EPS outlook amid rising costs.
5 days ago zacks.com
Big Day for Econ Data, Hyperscaler Earnings
We have a solid slate of reports today, both of the earnings variety and regarding economic growth.
-
5 days ago benzinga.com
Barclays Maintains Equal-Weight on Biogen, Raises Price Target to $230
Barclays analyst Emily Field maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and raises the price target from $200 to $230.
5 days ago zacks.com
Biogen (BIIB) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Biogen (BIIB) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics…
5 days ago benzinga.com
Biogen Q3 2026 Earnings Call Transcript
Biogen (NASDAQ:BIIB) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
5 days ago zacks.com
Biogen Inc. (BIIB) Tops Q3 Earnings and Revenue Estimates
Biogen Inc. (BIIB) came out with quarterly earnings of $2.62 per share, beating the Zacks Consensus Estimate of $2.06 per share. This compares to earnings of $4.81 per share a year ago.
5 days ago wsj.com
Biogen Swings to Loss, Logs Higher Sales
The biotechnology company said the swing to a loss was primarily due to transaction-related charges.
-
5 days ago benzinga.com
CORRECTION: Biogen Narrows FY2026 Adj EPS Guidance from $15.85-$16.85 to $15.95-$16.75 vs $12.36 Est
Biogen (NASDAQ:BIIB) narrows FY2026 Adj EPS guidance from $15.85-$16.85 to $15.95-$16.75 vs $12.36 analyst estimate..
-
5 days ago benzinga.com
Biogen Raises FY2026 GAAP EPS Guidance from $12.00-$13.00 to $12.20-$13.00 vs $5.84 Est
Biogen (NASDAQ:BIIB) lowers FY2026 Adj EPS guidance from $15.25-$16.25 to $12.20-$13.00 vs $12.36 analyst estimate..
1 week ago zacks.com
Biogen Q3 Preview: Will Growth Products Drive an Earnings Beat?
Biogen heads into Q3 earnings with growth from new drugs and acquisitions potentially offsetting declining multiple sclerosis sales.
1 week ago seekingalpha.com
Baron Health Care Fund: Q3 2026 New Positions And Exits
During the quarter, we added 4 new positions and exited 14, bringing the number of positions in the Fund to 33. We initiated a position in Biogen Inc., a company that we believe is in the early…
1 week ago zacks.com
Biogen (BIIB) Surges 5.3%: Is This an Indication of Further Gains?
Biogen (BIIB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the…
1 week ago gurufocus.com
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates
[url="]Stoke Therapeutics, Inc.[/url] (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential wit
-
1 week ago benzinga.com
B of A Securities Maintains Neutral on Biogen, Raises Price Target to $244
B of A Securities analyst Jason Zemansky maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $219 to $244.
1 week ago seekingalpha.com
Biogen Q3 Earnings Preview: Grounds For Optimism, But Disappointment The Norm
Biogen is rated Hold ahead of Q3 2026 earnings, with cautious optimism due to pipeline catalysts and improving growth portfolio performance. MS franchise and Alzheimer's therapies face patent…
1 week ago zacks.com
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
-
1 week ago benzinga.com
TD Cowen Maintains Buy on Biogen, Raises Price Target to $250
TD Cowen analyst Phil Nadeau maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $225 to $250.
1 week ago gurufocus.com
A Look at Biogen Inc (BIIB) After 4.1% Gain -- GF Value $202.16 vs Price $243.10
On October 20, 2026, Biogen Inc (BIIB) shares rose 4.1% to a current price of $243.10. This increase comes in the context of a 52-week range that saw lows of $1
1 week ago zacks.com
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now
BBIO, NTLA, BIIB and VKTX offer investors potential upside from promising drug pipelines and upcoming FDA decisions and pivotal study results.
-
1 week ago benzinga.com
Wells Fargo Maintains Overweight on Biogen, Raises Price Target to $310
Wells Fargo analyst Mohit Bansal maintains Biogen (NASDAQ:BIIB) with a Overweight and raises the price target from $250 to $310.
2 weeks ago defenseworld.net
Biogen Inc. $BIIB Shares Acquired by CWA Asset Management Group LLC
CWA Asset Management Group LLC raised its holdings in Biogen Inc. (NASDAQ: BIIB) by 11.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and…
-
2 weeks ago benzinga.com
Biogen To Demonstrate Data, Additional Scientific Presentations From Its Nephrology Portfolio At American Society Of Nephrology Kidney Week
Biogen Inc. (Nasdaq: BIIB) will present new EMPAVELI® (pegcetacoplan) data and additional scientific presentations from its nephrology portfolio, including investigational felzartamab, at the…
2 weeks ago globenewswire.com
Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week
CAMBRIDGE, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) will present new EMPAVELI® (pegcetacoplan) data and additional scientific presentations from its nephrology portfolio,…
2 weeks ago seekingalpha.com
Biogen: The Bull Case Is Extending Beyond Alzheimer's (Rating Upgrade)
In 12 days, on October 28, Biogen Inc. will publish its results for the third quarter. As a reminder, in late July, the company raised its FY 2026 non-GAAP diluted EPS underlying guidance from…
-
3 weeks ago benzinga.com
JP Morgan Upgrades Biogen to Overweight, Raises Price Target to $300
JP Morgan analyst Chris Schott upgrades Biogen (NASDAQ:BIIB) from Neutral to Overweight and raises the price target from $210 to $300.
-
3 weeks ago benzinga.com
RBC Capital Maintains Outperform on Biogen, Lowers Price Target to $256
RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers the price target from $260 to $256.
4 weeks ago benzinga.com
4 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
-
1 month ago benzinga.com
Biogen Announces Data From Phase 2 Part Of Its Current AMETHYST Phase 2/3 Trial Of Litifilimab In Participants With Cutaneous Lupus Erythematosus Demonstrates 27.2% Of Patients At Week 52 Achieve Clinical Endpoint Of Clear Or Utmost Clear Skin; Litifilimab Seen To Be Generally Well Tolerated
Biogen Inc. (NASDAQ:BIIB) today announced 52-week results from the Phase 2 part of the ongoing AMETHYST Phase 2/3 study (Part A) of litifilimab in people living with cutaneous lupus erythematosus…
1 month ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
-
1 month ago benzinga.com
Biogen Announces Publication Of Phase 3 VALIANT Adolescent Subgroup Data In CJASN Demonstrating 75% Proteinuria Reduction For EMPAVELI In Rare Kidney Diseases
EMPAVELI-treated adolescents achieved a 75% relative reduction in proteinuria within 6 months versus placebo EMPAVELI is the only approved treatment for adolescents with C3G and primary IC-MPGN,…
-
1 month ago benzinga.com
HSBC Maintains Reduce on Biogen, Raises Price Target to $175
HSBC analyst Rajesh Kumar maintains Biogen (NASDAQ:BIIB) with a Reduce and raises the price target from $165 to $175.